12:00 AM
 | 
Jun 25, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lyxumia lixisenatide: Additional Phase III data

Additional data from the double-blind, international Phase III GetGoal Duo 1 trial in 446 Type II diabetics inadequately controlled with oral anti-diabetic drugs showed that Lyxumia as an add-on to Lantus insulin glargine and metformin significantly reduced HbA1c from 8.6% at baseline to 6.96% at week 24, the primary endpoint, vs. 7.3% for placebo plus Lantus and metformin (p<0.0001). Patients received placebo or once-daily...

Read the full 307 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >